BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND FUS, P35637, 2521, ENSG00000089280, TLS/CHOP, FUS-CHOP, CHOP, FUS1, TLS AND Prognosis
68 results:

  • 1. Discovery of an independent poor-prognosis subtype associated with tertiary lymphoid structures in breast cancer.
    Liu R; Huang X; Yang S; Du W; Chen X; Li H
    Front Immunol; 2024; 15():1364506. PubMed ID: 38571938
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Rolapitant treats lung cancer by targeting deubiquitinase OTUD3.
    Du T; Gu Q; Zhang Y; Gan Y; Liang R; Yang W; Lu Y; Xu C; Wu J; Ma R; Cao H; Jiang J; Wang J; Feng J
    Cell Commun Signal; 2024 Mar; 22(1):195. PubMed ID: 38539203
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.
    Xiaoxu D; Min X; Chengcheng C
    BMC Pulm Med; 2024 Mar; 24(1):155. PubMed ID: 38532454
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
    Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
    BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis.
    Lin Y; Cao Q; Hong A; Liang X
    Clin Respir J; 2024 Mar; 18(3):e13741. PubMed ID: 38450981
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
    Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
    EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Low-dose radiotherapy promotes the formation of tertiary lymphoid structures in lung adenocarcinoma.
    Wang D; Huang L; Qian D; Cao Y; Wu X; Xu P; Ming L; Tang J; Huang Z; Yin Y; Zhou L
    Front Immunol; 2023; 14():1334408. PubMed ID: 38259481
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
    Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
    Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Spindle cell rhabdomyosarcomas: With TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature.
    Bradová M; Mosaieby E; Michal M; Vaněček T; Ing SK; Grossmann P; Koshyk O; Kinkor Z; Laciok Š; Nemcová A; Straka Ľ; Farkas M; Michal M; Švajdler M
    Histopathology; 2024 Apr; 84(5):776-793. PubMed ID: 38114270
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
    Liu Y; Xiong L; Chen Y; Cai R; Xu X; Wang T; Guo Y; Ruan L; Fang Y; Zhang Q; Shen B; Ye J; Zhou G
    Hum Vaccin Immunother; 2023 Dec; 19(3):2285902. PubMed ID: 38010104
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Circular RNA CircSATB2 facilitates osteosarcoma progression through regulating the miR-661/fus-mediated mRNA of ZNFX1.
    Wang Z; She D; Liu L; Hua X; Zhu H; Yu L; Wang H; Zhu Y; Fan G; Wang Y; Xu M; Zhou G
    Cell Signal; 2024 Feb; 114():110977. PubMed ID: 37984605
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Recent Progress of Tertiary Lymphoid Structure in prognosis and Immunotherapy of Non-small Cell lung cancer].
    Liu Y; Xiong L; Cai R; Chen Y; Ye J; Shen B; Zhou G
    Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):615-620. PubMed ID: 37752541
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta.
    O'Connor RA; Martinez BR; Koppensteiner L; Mathieson L; Akram AR
    Front Immunol; 2023; 14():1221532. PubMed ID: 37520560
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer.
    Lu H; Lou H; Wengert G; Paudel R; Patel N; Desai S; Crum B; Linton-Reid K; Chen M; Li D; Ip J; Mauri F; Pinato DJ; Rockall A; Copley SJ; Ghaem-Maghami S; Aboagye EO
    Cell Rep Med; 2023 Jul; 4(7):101092. PubMed ID: 37348499
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Tertiary lymphoid structures in pulmonary metastases of microsatellite stable colorectal cancer.
    Karjula T; Niskakangas A; Mustonen O; Puro I; Elomaa H; Ahtiainen M; Kuopio T; Mecklin JP; Seppälä TT; Wirta EV; Sihvo E; Yannopoulos F; Helminen O; Väyrynen JP
    Virchows Arch; 2023 Jul; 483(1):21-32. PubMed ID: 37337034
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Nimbolide Exhibits Potent Anticancer Activity Through ROS-Mediated ER Stress and DNA Damage in Human Non-small Cell lung cancer Cells.
    Chen X; Zhang H; Pan Y; Zhu N; Zhou L; Chen G; Wang J
    Appl Biochem Biotechnol; 2024 Jan; 196(1):182-202. PubMed ID: 37103738
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Intratumoral tertiary lymphoid structure (tls) maturation is influenced by draining lymph nodes of lung cancer.
    He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma.
    Xu X; Gao Y; Duan S; Ding Q; Wang X; Dai X; Zhang Y; Chen Y; Chen D
    Cancer Med; 2023 Apr; 12(8):9547-9558. PubMed ID: 36880167
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.